IL1A and Postpericardiotomy Syndrome: This 6-month study investigated the therapeutic potential of rilonacept, a once-weekly subcutaneously injected IL-1α and IL-1β cytokine trap in patients with both idiopathic and postpericardiotomy syndrome RP and in both acutely symptomatic as well as steroid-dependent clinical presentations.